Phospholipase A activity associated with membranes of human polymorphonuclear leucocytes

Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis

Secretory A(2) phospholipases (sPLA(2)) hydrolyze surfactant phospholipids cause surfactant dysfunction and are elevated in lung inflammation. Phospholipase-mediated surfactant hydrolysis may disrupt surfactant function by generation of lysophospholipids and free fatty acids and/or depletion of native phospholipids. In this study, we quantitatively assessed multiple mechanisms of sPLA(2)-mediated surfactant dysfunction using non-enzymatic models including supplementation of surfactants with exogenous lysophospholipids and free fatty acids. Our data demonstrated lysophospholipids at levels >or=10 mol% of total phospholipid (i.e., >or=10% hydrolysis) led to a significant increase in minimum surface tension and increased the time to achieve a normal minimum surface tension. Lysophospholipid inhibition of surfactant function was independent of the lysophospholipid head group or total phospholipid concentration. Free fatty acids (palmitic acid, oleic acid) alone had little effect on minimum surface tension, but did increase the maximum surface tension and the time to achieve normal minimum surface tension. The combined effect of equimolar free fatty acids and lysophospholipids was not different from the effect of lysophospholipids alone for any measurement of surfactant function. Surfactant proteins did not change the percent lysophospholipids required to increase minimum surface tension. As a mechanism that causes surfactant dysfunction, depletion of native phospholipids required much greater change (equivalent to >80% hydrolysis) than generation of lysophospholipids. In summary, generation of lysophospholipids is the principal mechanism of phospholipase-mediated surfactant injury in our non-enzymatic models. These models and findings will assist in understanding more complex in vitro and in vivo studies of phospholipase-mediated surfactant injury.

Phospholipase A2: its usefulness in laboratory diagnostics

Phospholipase A2 (PLA2) is an enzyme that catalyzes the hydrolysis of membrane phospholipids. This article reviews the source and structure of PLA2, the involvement of the enzyme in various biological and pathological phenomena, and the usefulness of PLA2 assays in laboratory diagnostics. Of particular importance is the role of PLA2 in the cellular production of mediators of inflammatory response to various stimuli. Assays for PLA2 activity and mass concentration are discussed, and the results of enzyme determinations in plasma from patients with different pathological conditions are presented. The determination of activity and mass concentration in plasma is particularly useful in the diagnosis and prognosis of pancreatitis, multiple organ failure, septic shock, and rheumatoid arthritis. A very important result is the demonstration that PLA2 is an acute phase protein, like CRP. Indeed, there is a close correlation between PLA2 mass concentration and CRP levels in several pathological conditions. Although the determination of C-reactive protein is much easier to perform and is routinely carried out in most clinical laboratories, the assessment of PLA2 activity or mass concentration has to be considered as a reliable approach to obtain a deeper understanding of some pathological conditions and may offer additional information concerning the prognosis of several disorders.

Differential activation of human neutrophil cytosolic phospholipase A2 and secretory phospholipase A2 during priming by 1,2-diacyl- and 1-O-alkyl-2-acylglycerols

We have shown previously that both 1,2-diacylglycerol (AAG) and 1-O-alkyl-2-acylglycerol (EAG) prime neutrophil release of arachidonic acid via uncharacterized phospholipases A2. Therefore, we investigated the actions of EAG and AAG specifically on neutrophil cytosolic (cPLA2) and secretory (sPLA2) phospholipase A2s. We hypothesized that AAG as a protein kinase activator would activate cPLA2 via phosphorylation events. EAG is antagonistic to the AAG activation of PKC, thus it was not expected to act via phosphorylation of cPLA2. Neutrophils were primed with either AAG or EAG and then stimulated with fMLP. When neutrophils were primed with 5-20 microM 1,2-diacylglycerol, a shift was observed in cPLA2 migration on SDS-PAGE gels, consistent with phosphorylation of the protein. This gel shift was not seen after exposure to EAG. AAG also caused a parallel increase in enzymatic activity of cPLA2 that was not seen with EAG. We also investigated whether either diglyceride would cause similar priming or direct secretion of sPLA2. Both AAG and EAG directly caused significant secretion of neutrophil sPLA2. EAG also increased the release of sPLA2 in cells subsequently stimulated with fMLP. Thus, AAG activated cPLA2 and stimulated secretion of sPLA2. In contrast, EAG did not activate cPLA2, but directly activated secretion of sPLA2. We also demonstrated that human synovial fluid sPLA2 increased AA release from resting and fMLP-stimulated neutrophils. Given that diglycerides prime for release of AA, PAF, and LTB4, these current data support the hypothesis that such priming may be mediated by phosphorylation dependent (cPLA2) or phosphorylation independent (e.g. secretion of sPLA2) events.

Type IB secretory phospholipase A2 is contained in insulin secretory granules of pancreatic islet beta-cells and is co-secreted with insulin from glucose-stimulated islets

Stimulation of pancreatic islets with d-glucose induces insulin secretion from secretory granules contained within the islet beta-cells. Accumulating evidence suggests that secretory phospholipases A2 (sPLA2) may play a role in the distal events of secretory processes in many different cell types. Since intact pancreatic islets have been reported to contain sPLA2, it was of interest to determine the cellular and subcellular localization of the sPLA2 enzymes in pancreatic islets. Our findings indicate that rat pancreatic islets express mRNA for both types IB and IIA sPLA2 enzymes and mRNA for an sPLA2 membrane receptor. Immunoblotting analyses with antibodies directed against type IB sPLA2 or against type IIA sPLA2 indicate that the type IB isoform is much more abundant than the type IIA isoform in islets. Studies with purified populations of islet beta-cells prepared from dispersed islet cells by fluorescence-activated cell sorting indicate that both sPLA2 activity and type IB sPLA2 immunoreactive protein are substantially more abundant in beta-cells than in non-beta-cells. Subcellular fractionation studies indicate that sPLA2 activity and type IB sPLA2 immunoreactive protein are contained in insulin secretory granules. Stimulation of intact islets with insulin secretagogues results in the co-secretion of insulin and of sPLA2 activity and type IB sPLA2 immunoreactive protein into the incubation medium. These findings raise the possibility that type IB sPLA2 participates in the secretory process of pancreatic islet beta-cells.

Secretory and cytosolic phospholipases A2 are activated during TNF priming of human neutrophils

Cytokines alter neutrophil (PMN) function during inflammation, and Tumor Necrosis Factor (TNF) in vitro primes PMN such that receptor-mediated stimulation causes markedly enhanced release of arachidonic acid. We hypothesized that two Ca(2+)-dependent PLA2's in PMN might be activated during priming of the cell, thus affecting arachidonate release. A low molecular weight, secretory PLA2 was identified by enzymatic activity in the cell free supernates of primed or stimulated PMN, and in PMN disrupted by nitrogen cavitation. The enzymatic activity was calcium-dependent, acid stable, destroyed by dithiothreitol, and blocked by anti-sPLA2 antibodies. TNF caused secretion of sPLA2 and also caused an increase in cell-associated sPLA2 enzymatic activity. Activation and release were maximal with fMLP stimulation of TNF-primed PMN. Neutrophils also contained a cytosolic PLA2 (cPLA2) characterized by enzymatic activity which was calcium dependent, enhanced by dithiothreitol, and blocked by anti-cPLA2 antibody. TNF caused a doubling of cPLA2 enzymatic activity which was associated with phosphorylation of the enzyme as judged by a migration shift on Western blots. Thus, TNF priming of human PMN caused marked increase in fMLP stimulated AA release in parallel to enhanced activity of two different PLA2's.

Distribution of pancreatic (group I) and synovial-type (group II) phospholipases A2 in human tissues

The catalytic activity of phospholipase A2 (cat-PLA2) and the concentration of pancreatic (group I) phospholipase A2 (pan-PLA2) and synovial-type (group II) phospholipase A2 (syn-PLA2) were studied in 19 human tissues in order to find potential sources of circulating phospholipase A2. Five specimens of each tissue were collected at autopsies or from normal deliveries (placentas and amnionic membranes). The concentrations of pan-PLA2 and syn-PLA2 were measured by specific time-resolved fluoroimmunoassays. The cat-PLA2 was measured by radioactive dipalmitoyl phosphatidylcholine as substrate. The concentration of pan-PLA2 was negligible in all tissue homogenates except the pancreas. Immunoreactive syn-PLA2 was found in the homogenates of the digestive tract, cartilage, and prostatic and parotid glands. By immunohistochemistry, syn-PLA2 was localized in Paneth cell secretory granules, chondrocytes, cartilage matrix, and glandular cells of prostate.

Cloricromene inhibits leukotriene formation by human polymorphonuclear leucocytes by suppressing arachidonate release from membrane phospholipids

Cloricromene, an antithrombotic agent known to inhibit the release of arachidonic acid (AA) in stimulated human platelets, was tested for its effects on arachidonate release and metabolism in human polymorphonuclear leucocytes (PMNs). Cloricromene dose-dependently suppressed the release of leukotriene B4 (LTB4), as assessed by radioimmunoassay, from both isolated PMNs and human whole blood stimulated with the calcium ionophore A23187 or with serum-treated zymosan (STZ). The inhibitory effect was higher when the concentration of the stimulating agent was weaker. Cloricromene also inhibited dose-dependently the liberation of LTB4, LTC4, LTD4 and 5-hydroxy-6,8,11,14-eicosatraenoic acid as assessed by HPLC in the supernantant of A23187-stimulated PMNs. Finally, the drug was able to suppress the release of [3H]AA from purified human PMNs prelabeled with the radioactive fatty acid and stimulated with either A23187 or with STZ. The A23187-induced decrease in the radioactivity of phosphatidylinositol, the phospholipid class mainly involved in AA release in stimulated PMNs, was also inhibited by cloricromene. Cloricromene suppresses leukotriene formation in human PMNs by reducing AA release from membrane phospholipids, possibly through interference with phospholipase A2 activation; this activity may contribute to the leucocyte-inhibitory effects reported previously for cloricromene.

Phospholipase A2 in human ascitic fluid. Purification, characterization and immunochemical detection

A phospholipase A2 (PLA2, EC 3.1.1.4) was purified from human cell-free ascitic fluid (a-PLA2) by ion-exchange chromatography and h.p.l.c. on a reverse-phase column to apparent homogeneity. The enzyme had an Mr of approx. 10,000 as determined by SDS/PAGE. Polyclonal antibodies raised in a rabbit were specific to a-PLA2, as judged by immunoblotting. A time-resolved fluoroimmunoassay (TR-FIA) for measuring the concentration of a-PLA2 in various body fluids was developed. The detection limit of the assay was about 6 ng/ml. The antiserum did not cross-react with pancreatic secretory phospholipase A2 as measured by TR-FIA. The enzyme content was studied in various samples, including normal human serum, buffy-coat leucocytes, synovial fluid, and pancreas and spleen homogenates.

Subcellular distribution of fatty acids, phospholipids and phospholipase A2 in human neutrophils

We have examined the putative relationship between the presence of neutral pH optimum phospholipase A2 activities and the phospholipid and fatty acid composition in the distinct fractions obtained after subcellular fractionation in a continuous sucrose gradient of human neutrophils. Neutral phospholipase A2 activity was found mainly in the plasma membrane, the azurophilic granules and an unidentified fraction which was a little denser than that containing specific granules and endoplasmic reticulum. These differently located phospholipase A2 activities resulted in activation upon calcium ionophore A23187-cell treatment, but the phospholipase A2 activity found in the unidentified region showed the highest degree of activation after cell treatment with A23187 and hydrolyzed preferentially ethanolamine-containing glycerophospholipids. The subcellular distribution of inositol-containing phosphoglycerides was bimodal, with a main peak at the plasma membrane and another peak at the azurophilic granule region. Choline- and ethanolamine-containing glycerophospholipids showed a broad distribution throughout the gradient, with preponderance in the denser part of the gradient, where the intracellular organelle phospholipase A2 activities were located. Interestingly, ethanolamine-containing glycerophospholipids were shown to be enriched in fractions containing the phospholipase A2 which hydrolyzes preferentially this phospholipid class. Most of the arachidonic acid present in the postnuclear fraction of human neutrophils was found in the plasma membrane and resulted to be the only fatty acid released during A23187 stimulation. Thus, plasma membrane phospholipase A2 seems to be involved mainly in the release of arachidonic acid in A23187-stimulated cells. These findings indicate that differences in substrate specificity found in vitro among the phospholipase A2 activities located in distinct subcellular particulates might be a reflection of the distinct phospholipid and fatty acid composition in these particulates.

The metabolism of arachidonic and eicosapentaenoic acids in human neutrophils stimulated by A23187 and FMLP

A23187 stimulates the metabolism of endogenous as well as exogenous arachidonic acid (AA) and eicosapentaenolc acid (EPA) to their corresponding leukotrienes in human neutrophils. In contrast, conflicting results have been obtained concerning the effect of FMLP on the metabolism of these fatty acids. In the present study we compared the effect of A23187 and FMLP on the release and metabolism of these fatty acids in neutrophils. Stimulation of neutrophils with A23187, but not with FMLP, resulted in detectable levels of AA in the presence or absence of BW755C (a dual inhibitor of cyclooxygenase and lipoxygenase). The absolute amount of nonesterified AA in the extracts of neutrophils exposed to the agonist A23187 in the presence of BW755C was 20% higher than that obtained in the absence of BW755C, indicating that only a small fraction of the released AA was converted to lipoxygenase products. Furthermore, significant quantities of AA and EPA metabolites were detected only after treatment of neutrophils with A23187, but not with FMLP. Both A23187 and FMLP stimulated the conversion of exogenous EPA to 5-lipoxygenase products, with A23187 being somewhat more effective. In addition, significant differences were noted on the effect of EPA and DHA on the conversion of AA to its metabolites in A23187-stimulated neutrophils. Our results provide strong evidence that the amounts of eicosanoid precursors mobilized in response to FMLP are extremely small, if any, and this appears to be the likely explanation for the lack of eicosanoid detection by HPLC in FMLP-stimulated neutrophils.

Serum phospholipase A in hematological diseases

Inflammatory cells, e.g., neutrophils, monocytes, and macrophages are presumed to be a source of circulating phospholipase A in nonpancreatic diseases. Therefore, we investigated in a preliminary study whether serum phospholipase A activity is related to leukocyte counts in 43 patients with hematological diseases. Serum PLA activity was significantly increased in patients with Hodgkin's disease, acute monocytic leukemia, myelofibrosis with myeloid metaplasia, and polycythemia vera when compared with patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute myelogenous leukemia, but did not correlate with total leukocyte counts.

Prognostic value of serum phospholipase A in the multitraumatized patient

Phospholipase A serum activity was prospectively studied in 39 patients with multiple trauma. There was no correlation of phospholipase A activity with type or severity of injury. With increasing phospholipase A levels, a rise in mortality was found. A prediction of fatal outcome on an individual basis was not possible. The sensitivity for complications was 90%, whereas the predictive value of the positive test (64%) and specificity (47%) were low. When the behavior of phospholipase A and elastase release were compared, no correlation between these two parameters could be detected. Therefore, PMN leukocytes do not seem to be a major source of phospholipase A in serum.

Serum phospholipase--regulatory and pathophysiological aspects

The development of a photometric procedure to measure phospholipase A activity has extended previous observations that this enzyme activity increases in several pathological states including pancreatic and inflammatory diseases. Serum phospholipase A in pancreatitis was characterized as a mixture of the pancreatic enzyme and a different phospholipase with a pH optimum at 8.0. The latter enzyme was also observed in nonpancreatic diseases like septicemia and acute lung failure which are characterized by an increase in tissue phagocyte activity. The possible pathogenic role of phospholipase(s) A, their intracellular regulation and the proposed mechanisms of release into the blood stream are discussed with respect to the present pathobiochemical knowledge. This includes the mechanism of activation of phagocytosis and the possible role of lipocortins known to be stimulated by glucocorticoid treatment.

Phospholipid metabolism in polymorphonuclear leukocytes from rheumatoid arthritis patients: effects of non-steroidal anti-inflammatory agents and clotrimazole

Arachidonic acid (AA) metabolism and phospholipase A2 (PLA2) activity were measured in the peripheral blood polymorphonuclear leukocytes (PMNL) from ten patients with rheumatoid arthritis (RA) on treatment with various non-steroidal anti-inflammatory agents (NSAIA). AA metabolism and PLA2 activity were measured both initially and after treatment with either placebo or Clotrimazole, a broad spectrum anti-mycotic agent, as a possible anti-rheumatic drug. AA metabolism was also measured in PMNL from ten patients with active RA untreated with any NSAIA and ten normal volunteers. Using 3H-AA prelabeled cells, we show that there was a significantly higher (P less than 0.025) production of 3H-LTB4 in response to stimulation with the calcium ionophore A23187 in untreated RA patients than in normal volunteers (mean +/- S.D.:4.8 +/- 1.6% and 3.1 +/- 1.0%, respectively). The production of 3H-LTB4 by PMNL from patients on NSAIAs was less elevated (mean +/- S.D.:4.1 +/- 1.5%) and was not significantly different from normal controls. Concurrently we examined PLA2 activity in PMNL-sonicates from ten of our study patients using autoclaved [14C]oleate-labeled E. coli biomembranes as an exogenous substrate. Using linear regression analysis, we demonstrate a significant correlation between in vitro PLA2 activity and the release of 3H-AA from the cellular phospholipids (deacylation) in response to A23187 stimulation (r = -0.526, P less than 0.025). We also demonstrate significant correlations between the overall clinical state of the RA patient, as evaluated by a modified rheumatoid activity index (MRAI), and both the release of 3H-AA from the cellular phospholipids and its production of total [3H]eicosanoids (r = -0.557, P less than 0.025 and r = 0.644, P less than 0.005, respectively). This data suggests that: PLA2 activity may, in part, account for the higher generation of LTB4 by RA PMNL; NSAIAs may be capable of modulating this abnormality; and Clotrimazole may affect the clinical or laboratory data of RA patients already on treatment with NSAIA.

Phospholipase A2 in macrophage plasma membrane releases arachidonic acid from phosphatidylinositol

A high level of arachidonic acid release from [2-14C]arachidonylphosphatidylinositol (PI) was observed at neutral pH (6.0-7.0) in the presence of purified plasma membranes of guinea pig peritoneal macrophages. This activity was at least 10-fold higher than that with arachidonylphosphatidylcholine (PC) or phosphatidylethanolamine (PE) as substrate. The accumulation of [14C]diacylglycerol and [14C]phosphatidic acid was not detected at any time, and arachidonic acid release from [14C]arachidonyldiacylglycerol was not detectable either. The data suggest that arachidonic acid release from PI may not occur via the phospholipase C pathway. In this paper, we demonstrate the possibility that arachidonic acid release from PI at neutral pH in the macrophage plasma membrane is dependent on the action of phospholipase A2 (EC 3.1.1.4) -like activity. The maximum arachidonic acid release was dependent upon both pH and substrate. Particularly, the activity of arachidonic acid release from PI at neutral pH was very high compared with that from PC or PE. We suggest that phosphatidylinositol phospholipase A2 (EC 3.1.1.52) may play an important role in providing arachidonic acid for subsequent metabolic activity in the macrophages.

Lysophosphatidylcholine and the inflammatory action of neutrophils

Lysophosphatidylcholine (lysoPC) is a polar lipid formed in cells and tissues under normal conditions and is known to cause tissue damage in a variety of experimental systems. We have therefore examined the possibility that increased amounts of lysoPC are formed in activated inflammatory cells and are involved in their tissue-damaging action. Human neutrophil leucocytes were labelled with [14C]arachidonic acid (AA), activated with the calcium ionophore A23187, and the degradation of phospholipids, with subsequent release of AA and AA metabolites, was studied. We also studied neutrophil metabolism of [14C]lysoPC in the presence of different concentrations of cold lysoPC, and the relation between phospholipid degradation and release of N-acetyl-beta-glucosaminidase (NAG), a lysosomal enzyme. We found that the release of both AA and NAG was coupled to a degradation of phosphatidylcholine (PC), and that the neutrophils were able to metabolise lower, but not higher, concentrations of lysoPC. Moreover, the phospholipase A2 inhibitor, nordihydroguaiaretic acid significantly inhibited PC degradation, lysoPC formation, and NAG release, whereas the lipoxygenase inhibitor, BW 755C had little effect on these parameters. These findings demonstrate that the AA mobilization in activated neutrophils is associated with PC degradation, and point to be possibility that the ensuing lysoPC formation might mediate lysosomal enzyme release.

Pancreatic phospholipase A2: isolation of the human gene and cDNAs from porcine pancreas and human lung

Oligonucleotide probes synthesized using the published protein sequence for porcine pancreatic phospholipase A2 (PLA2; Puijk et al., 1977), were used to screen a cDNA library made from porcine pancreas. One resulting clone which encoded the entire porcine PLA2 enzyme was then used to screen various human cDNA and gene libraries. A 562-bp cDNA clone from human lung and two overlapping genomic clones encoding the identical transcript were obtained. These clones encoded a 126-residue peptide corresponding to human "pancreatic" PLA2. The gene spanned 4.9 kb and contained three introns of 1692, 800, and about 2650 bases, respectively. Hybridization of the human cDNA against blots of total human DNA detected the same set of fragments contained in both genomic clones and failed to detect more than one distinct gene. Under equivalent conditions, the same probe detected two discrete bands in cobra (Naja naja) genomic DNA. Apparently, there is a single or small number of identical human genes encoding "pancreatic" PLA2 which are transcribed also in lung tissue; human pancreatic PLA2 appeared more closely related at the nucleotide level to snake counterparts than to other reported human PLA2 enzyme forms.

Endogenous suppression of neutral-active and calcium-dependent phospholipase A2 in human polymorphonuclear leukocytes

Phospholipase A2 activity was measured in homogenized and acid-extracted human polymorphonuclear leukocytes using [1-14C]oleate-labelled autoclaved Escherichia coli as substrate. In whole homogenate and in the supernatant and particular fractions separated by centrifugation at 150,000 X g, phospholipase activity was barely detectable (1-4 pmol/h per 10(6) cell equivalents). By contrast, acid extracts of these fractions contained over 10-times as much phospholipase activity in the dialyzed supernatants (20-300 pmol/h per 10(6) cell equivalents), whereas phospholipase inhibitor(s) were found in the sediment. The acid-solubilized phospholipase A2 activity was absolutely Ca2+-dependent and optimal at pH 7.0-7.5 with 1.0 mM added Ca2+. Addition of the resuspended sediment of the acid extract dose-dependently suppressed phospholipase activity in the supernatant; less than equivalent amounts were sufficient to inhibit 95%. Suppressor activity was lipid-extractable. After thin layer chromatography of lipid extracts, the bulk of inhibitory activity was recovered from the free fatty acid region. Analysis of the fatty acids by gas liquid chromatography showed that 63% were unsaturated. All unsaturated fatty acids tested were potent inhibitors of phospholipase A2 activity (IC50 3-10 microM). Oleoyl-CoA, hydroxyeicosatetraenoic acids and leukotriene D4 were also inhibitory, while methyl oleate, saturated fatty acids and the prostaglandins E2 and F2 alpha had no effect. These in vitro data indicate that neutral-active and calcium-dependent phospholipase A2 in human polymorphonuclear leukocytes is largely suppressed by endogenous inhibitors and suggest that unsaturated fatty acids and some of their metabolites may partly account for this suppressor activity.

A cytosolic phospholipase in human neutrophils that hydrolyzes arachidonoyl-containing phosphatidylcholine

In stimulated neutrophils the production of eicosinoids and the lipid mediator, platelet-activating factor, is thought to be initiated by the activation of a phospholipase A2 which cleaves arachidonic acid from choline-containing glycerophospholipids. Accordingly, studies were undertaken in human neutrophils to characterize phospholipase enzymes that can hydrolyze 1-acyl- and 1-alkyl-linked arachidonoyl-containing phosphatidylcholine (PC). Cellular homogenates were incubated with sonicated dispersions of the arachidonoyl-labeled phospholipid substrates and the hydrolysis of radiolabeled arachidonate was measured. The phospholipase activity was cytosolic, optimal at pH 8.0, and calcium dependent. The homogenization conditions used were important in determining the amount of recoverable enzymatic activity. Vigorous sonication and the presence of calcium during homogenization were strongly inhibitory, whereas the presence of EGTA, heparin and proteinase inhibitors during homogenization increased the activity. Competitive experiments with unlabeled substrates suggested that the phospholipase hydrolyzed arachidonic acid equally well from either 1-acyl- or 1-alkyl-linked PC. However, the phospholipase did show specificity for arachidonic acid, compared to oleic or linoleic acids, at the sn-2 position of 1-acyl-linked PC. When neutrophils were first stimulated with the ionophore A23187, the phospholipase activity against 1-O-hexadecyl-2-[3H]arachidonoylglycerophosphocholine (GPC) increased in a time-dependent fashion up to 3.5-fold over the unstimulated level. The activity against 1-palmitoyl-2-[3H]arachidonoyl-GPC also increased after ionophore stimulation but to a lesser extent. The results demonstrate the presence of a cytosolic, activatable phospholipase that may be involved in PC turnover, arachidonic acid release, and platelet-activating factor production in human neutrophils.

Phospholipid metabolism in human neutrophils activated by N-formyl-methionyl-leucyl-phenylalanine. Degranulation is not required for release of arachidonic acid: studies with neutrophils and neutrophil-derived cytoplasts

Neutrophils respond to chemoattractants by aggregating, degranulating, remodelling of phospholipids and releasing arachidonic acid. To determine whether ligand-induced remodelling of phospholipids depends on redistribution of intracellular organelles (degranulation), we compared phospholipid remodelling of human neutrophils with that of neutrophil-derived cytoplasts. Cytoplasts, organelle-depleted vesicles of cytosol surrounded by plasmalemma, cannot degranulate. Without a stimulus, [3H]arachidonate was incorporated preferentially into phosphatidylinositol (PI) and phosphatidylcholine (PC). Exposure of cytoplasts and neutrophils prelabelled with [3H]arachidonate or [14C]glycerol to fMet-Leu-Phe (10(-7) M) induced rapid changes in distribution of label and mass of individual phospholipids: [3H]arachidonate in phosphatidic acid (PA) increased 500% (120 s), [14C]glycerol incorporation and mass of PA approached 200% of unstimulated values, and [3H]arachidonate in PI decreased continuously; these data are compatible with activity of a PI/PA cycle. However, the mass of PI in both preparations and [14C]glycerol label in intact neutrophils increased initially (5 s), suggesting net synthesis and mobilization of more than one pool of PI. Heterogeneity of PC pools was also observed: [3H]arachidonate was lost from PC immediately upon addition of stimulus, whereas mass and [14C]glycerol values increased. Thus, net phospholipid synthesis, redistribution of arachidonate and activation of the PI/PA cycle are immediate responses of the neutrophil to receptor occupancy by chemoattractants. Furthermore, the similarity in response to fMet-Leu-Phe of neutrophils and granule-free cytoplasts indicates that these processes are independent of degranulation.

Contamination of commercial preparations of xanthine oxidase by a Ca2+-dependent phospholipase A2

Using [1-14C]oleate-labelled autoclaved Escherichia coli as substrate, we demonstrate that many, but not all, commercial preparations of xanthine oxidase contain phospholipase A2 activity as a contaminant. Phospholipase A2 activity (64.3-545.6 nmol phospholipid hydrolyzed per min per mg protein) was optimal in the neutral to alkaline pH range, was Ca2+-dependent, and was unaffected by the addition of xanthine. Phospholipase A2 activity was totally inhibited by 1.0 mM EDTA while radical production by xanthine plus xanthine oxidase was unaffected by EDTA. Even chromatographically purified xanthine oxidase (Sigma Grade III) contained substantial phospholipase A2 activity (64.3 nmol/min per mg). Since the preparation of xanthine oxidase employs proteolytic digestion of milk or buttermilk by pancreatin, an extract of pancreas which is an organ rich in phospholipase A2 activity, we speculate that the contaminant phospholipase A2 is introduced by this treatment. Because xanthine oxidase is used extensively to study free radical-induced cell injury and membrane phospholipid alterations, the presence of a potent extracellular phospholipase A2 may have influenced previously published reports and such studies in the future should be interpreted with care.

Phospholipid metabolism in human neutrophil subfractions

We describe a procedure for isolating human neutrophil subfractions by sucrose density centrifugation following nitrogen cavitation. Using this procedure we were able to isolate and characterize a cytosolic fraction, two separate plasma membrane-enriched fractions, and specific and azurophilic granule fractions. We used this procedure to examine the subcellular localization of the enzymes and substrates involved in the release of arachidonic acid from cellular phospholipids in response to whole cell stimulation. Whole cells were prelabeled for 2 h with [3H]arachidonic acid and [14C] stearic acid. When prelabeled cells were challenged with calcium ionophore A23187 (2 microM) for 5 min at 37 degrees C, each membrane-associated fraction, including both plasma membrane fractions and specific and azurophilic granule fractions, exhibited deacylation of phosphatidylinositol (PI) and phosphatidylcholine (PC). The specific granule fraction exhibited the greatest proportion of deacylation from PI while the more dense plasma membrane fraction was deacylated to a much lower extent than the other fractions. In terms of mass, the azurophilic granules deacylated the greatest amount of radiolabeled arachidonic acid. Although all membrane fractions may be sources of arachidonic acid to some extent, the azurophilic granule fraction may contain the largest pool of radiolabeled arachidonic acid that is released upon cell stimulation.

Electron microscopic study of phagocytosis of Escherichia coli by human polymorphonuclear leukocytes

The fate of Escherichia coli strains within the polymorphonuclear leukocytes was studied by determining the killing of bacteria, measuring the release of degradation products, and examining the phagocytic bacteria by electron microscopy. When sufficiently opsonized, both unencapsulated and encapsulated E. coli strains were rapidly phagocytized by polymorphonuclear leukocytes. Once phagocytized, the two unencapsulated E. coli strains (K-12 and O111) were rapidly killed (99% of the bacteria were killed during the first 5 min of phagocytosis) and extensively degraded (about 40% of the radiolabeled material was released from bacteria after 15 min of phagocytosis). Electron micrographs taken after 15 min of phagocytosis revealed extensive structural changes in most of the internalized bacteria. In contrast to the rapid killing and extensive breakdown of these strains, encapsulated E. coli O78:K80 was more resistant to killing and withstood degradation by polymorphonuclear leukocytes (only 5% of the radioactivity was released from the radiolabeled bacteria after 1 h of phagocytosis). Electron micrographs of thin sections taken after 1 h of phagocytosis revealed virtually no structural changes. Most of the internalized bacteria were still surrounded by thick capsular material.

Phospholipase A2 activity in rat and human lymphocytes

Partial characterization of phospholipase A from rat and human lymphocytes showed that it was much less active in man than in rat. The use of phosphatidylethanolamine labelled in the 2 position as substrate established that phospholipase A activity was 2 acyl-specific. It was maximal at pH 7.0 to 8.0, totally Ca2+ dependent and inhibited by detergents and Indomethacin.

Calmodulin content and activity of Ca2+-ATPase and phospholipase A2 in rat Kupffer cells

A protein resembling calmodulin was isolated from non-parenchymal and parenchymal cells of rat liver by affinity chromatography. The biological activity of the purified protein was assessed by the bovine brain cAMP phosphodiesterase assay. A highly sensitive radioimmunoassay as well as the cAMP phosphodiesterase method were employed to determine the calmodulin content of crude extracts from monolayer cultures of rat Kupffer cells and hepatocytes. An ATP-dependent, calmodulin-enhanced calcium transport was demonstrated in a membrane fraction of the non-parenchymal cells. Phospholipase A2 activity specific for 2-arachidonoyl phosphatide and with a pH optimum of 8.1 was measured in homogenized Kupffer cells; it was stimulated by agents previously shown to enhance prostaglandin synthesis in Kupffer cells, e.g. zymosan particles and lipopolysaccharide isolated from Salmonella minnesota. The increase in activity was completely prevented by pretreatment with or simultaneous addition of R 24571, a known calmodulin antagonist. However, if this inhibitor or calmodulin was added to the cell-free extract phospholipase A2 activity was not influenced. Phospholipase A1 activity could be detected at pH 5 only, showing a slight decrease in the homogenate of stimulated macrophages. Acyltransferase activity was high but independent of treatment of the Kupffer cells.

Surface-active phospholipase A2 in mouse spermatozoa

The partial characterization of a calcium-dependent phospholipase A2 associated with membranes of mouse sperm is described. Intact and sonicated sperm had comparable phospholipase A2 activity which was maximal at pH 8.0 using [1-14C]oleate-labeled autoclaved Escherichia coli or 1-[1-14C]stearoyl-2-acyl-3-sn-glycerophosphorylethanolamine as substrates. More than 90% of the activity was sedimented when the sperm sonicate was centrifuged at 100 000 X g, indicating that the enzyme is almost totally membrane-associated. The activity is stimulated 200% during the ionophore-induced acrosome reaction and is almost equally distributed between plasma/outer acrosomal and inner acrosomal membrane fractions. The membrane-associated phospholipase A2 had an absolute requirement for low concentrations of Ca2+; Sr2+, Mg2+ and other divalent and monovalent cations would not substitute for Ca2+. In the presence of optimal Ca2+, zinc and gold ions inhibited the activity while Cu2+ and Cd2+ were without effect. Incubation of sperm sonicates with 1-[1-14C]stearoyl-2-acyl-3-sn-glycerophosphorylethanolamine in the presence and absence of sodium deoxycholate demonstrated the presence of phospholipase A2 and lysophospholipase activities. No phospholipase A1 activity was detectable. Indomethacin, sodium meclofenamate and mepacrine, but not dexamethasone or aspirin, inhibited the sperm phospholipase A2 activity. Preincubation with p-bromophenacyl bromide inhibited phospholipase A2, suggesting the presence of histidine at the active site. The enzyme may play an important role in the membrane fusion events in fertilization.

Release of phospholipase A2 activity from rabbit peritoneal neutrophils by f-Met-Leu-Phe

Rabbit peritoneal neutrophils secrete phospholipase A2 activity in response to f-Met-Leu-Phe (FMLP). The secretion of phospholipase A2, like that of the known granule enzymes, requires cytochalasin B and is enhanced by extracellular Ca2+, and the time course of the release is rapid, being completed in less than a minute. The concentration dependence of the secretion of the phospholipase is the same as that of the known granule enzymes up to 10(-9) M FMLP. At this concentration, the release of the known granule enzymes reaches a maximum, but that of phospholipase A2 does not until 10(-8) M FMLP. The amount of enzyme activity released plus the amount of enzyme activity remaining in the pellet is distinctly greater than the total enzyme activity extractable from the cell before release. The phospholipase secreted is active in the neutral to alkaline range, requires Ca2+, is inhibited by low levels of detergent, and is of A2 specificity.

Mechanism of arachidonic acid release in human polymorphonuclear leukocytes

Previous studies have demonstrated that [3H]arachidonic acid is released from prelabeled human neutrophil phospholipids when the cells are stimulated by calcium ionophore A23187 or by opsonized zymosan. Neither lysophospholipid generated by phospholipase A2 activity, diacylglycerol nor monoacylglycerol produced via phospholipase C/diacylglycerol lipase action have been identified following neutrophil challenge. The inability to detect any intermediates during the release of arachidonate is due to either rapid reacylation of lysophospholipid or conversion of diacylglycerol (monoacylglycerol) to cellular acylglycerols. The addition of exogenous [14C]fatty acid at the time of challenge was employed to determine the involvement of either phospholipase A2 or phospholipase C activities. Neutrophil stimulation with calcium ionophore A23187 resulted in an incorporation of exogenous [14C]arachidonate into phosphatidylinositol and phosphatidylcholine, those phospholipids which specifically release arachidonate. When the saturated fatty acid, [14C]stearate, replaced [14C]arachidonate, very little [14C]fatty acid was incorporated into any of the phospholipid species. Lipid phosphorus measurements revealed no significant mass change in any phospholipid class following ionophore challenge. Production of [14C]phosphatidic acid was not detected, as would be expected if diacylglycerol kinase and de novo phospholipid metabolism were significantly involved.

Characterization of phospholipase A2 activity in rat aorta smooth muscle cells

Phospholipase A activity was measured in homogenates and acid extracts of smooth muscle cells from rat aorta and mesenteric artery using [1-14 C]oleate-labeled autoclaved Escherichia coli and 1-[1-14C]stearyl-2-acyl-3-sn-glycerophosphorylethanolamine as substrates. The results demonstrate the presence of neutral-active phospholipase(s) A that exclusively catalyze the release of fatty acid from the 2-position of phospholipids. Optimal activity was at pH 7.5, and there was an absolute requirement for low concentrations of Ca2+. Mg2+ did not substitute for Ca2+, and EGTA inhibited the activity. Phospholipase A2 activity was predominantly membrane-associated and was solubilized by homogenization in 0.18 N H2SO4. Sulfuric acid extracts of rat aortic smooth muscle cells were four times more active than extracts of mesenteric artery (710 vs. 170 nmol/h per mg protein). By comparison, acid extracts of rat lung, heart, and liver were less active (60-75 nmol/h per mg). Indomethacin, sodium meclofenamate, mepacrine and chlorpromazine, but not dexamethasone or aspirin, inhibited acid-solubilized phospholipase(s) A2 between 10(-6) and 10(-3) M in a dose-dependent manner. Preincubation with p-bromophenacyl bromide or diethylpyrocarbonate inhibited phospholipase(s) A2, suggesting the presence of a histidine residue at the active site. An extract from the leaves of feverfew plant (Tanacetum parthenium) was also a potent inhibitor of aortic smooth muscle phospholipase(s) A2.

Lysophospholipase activity of bovine adrenal medulla. A reevaluation

1. Chromaffin granule preparations isolated from bovine adrenal medulla hydrolyzed endogenous lysophosphatidylcholine (lyso-PC) and generated lysophosphatidylethanolamine when dialyzed at pH 7.5. 2. Undialyzed granule preparations hydrolyzed exogenously added [1-14C]palmitoyl-lyso-PC maximally (12-16 nmol/min per mg) at pH 7.5. At a given concentration of protein, activity increased with increasing concentrations of substrate lyso-PC to a maximum beyond which substrate inhibited activity up to 95%. 3. More than 95% of the lysophospholipase activity of fresh granule preparations toward exogenously added lyso-PC was inactivated irreversibly by dialysis. 4. By contrast, fresh microsomal preparations from adrenal medulla had similar substrate requirements for maximal lysophospholipase activity, but more than 35% of the activity was retained at high substrate concentrations or after extensive dialysis. 5. We conclude that adrenal organelles, other than microsomes, contain potent membrane-associated lysophospholipase activity that is inactivated preferentially by high detergent-substrate concentrations and/or dialysis. These observations suggest that lysophospholipase activity (and perhaps phospholipase A activity) is more widely distributed in organelle membranes of the adrenal medulla than was reported previously.

ATP-driven Ca2+ pump activity of macrophage and neutrophil plasma membrane

The results of the investigations here described permit us to conclude that macrophages and neutrophils have a peripheral, outwardly directed Ca2+ extrusion system, which is very similar to the well known Ca2+ pump of the red cell, with regard to capacity and mechanism (16, 21, 29). In fact, all the three cell types have similar maximum pumping rates (about 0.1-0.2 microgram-ions Ca2+/min/ml cells) and use ATP for extruding Ca2+. Furthermore, the plasma membrane of all the three cell types catalyzes a Ca2+-dependent ATPase reaction, which is very likely the enzyme manifestation of the Ca2+ pump activity. Further investigation is needed to establish whether the peripheral Ca2+ pump system of macrophages and neutrophils is utilized to restore steady-state levels of cytosolic Ca2+ upon cell stimulation, or is somehow involved in the triggering of cell response to various stimuli. In fact impairment of the pump activity by a cell stimulant would unbalance Ca2+ passive leaks and active cation extrusion, thereby leading to higher steady-state levels of Ca2+ in the cytosol and to stimulation of Ca2+-dependent functions (1-12).

Renal inner medullary prostaglandin synthesis. A calcium-calmodulin-dependent process suppressed by urea

Previous studies have demonstrated that hyperosmolar NaCl and mannitol stimulate immunoreactive prostaglandin E (iPGE) production by slices of inner medulla (IM), whereas urea inhibits this process. In the present study, the roles of Ca2+ and calmodulin in the control of PGE synthesis in IM and the basis for the differential actions of solutes were examined. A23187 increased [14C]arachidonate (AA) release and iPGE accumulation in the presence but not in the absence of media Ca2+ whereas stimulation by hypertonic NaCl or mannitol was well expressed with Ca2+ or in Ca2+-free buffer containing 2 mM EGTA. Hypertonic urea and trifluoperazine (TFP), an inhibitor of actions of the Ca2+-CaM complex, suppressed increases in [14C]AA release and iPGE induced by A23187, NaCl, or mannitol. By contrast, increases in iPGE in response to exogenous AA were not altered by urea or TFP. Ca2+ (25-100 microM) increased acyl hydrolase (AH) activity in EGTA washed (4 degrees C) 100,000 g particulate fractions of IM threefold, thereby restoring AH activity to the higher basal values of particulate fractions not washed with EGTA. This action of Ca2+ was blocked by hypertonic urea of TFP, whereas AH activity was not influenced by NaCl or mannitol in the presence or absence of Ca2+. In contrast to their effects on AH activity, hypertonic urea and TFP did not alter conversion of AA to PGE2, PGF2 alpha, or PGD2 by IM microsomal fractions. Ca2+-induced increases in particulate AH were blunted after partial depletion of endogenous CaM-like activity. Ca2+ action was restored by addition of purified exogenous CaM, but not by addition of other small acidic proteins, including troponin C. The findings support a role for CaM in the regulation of PGE synthesis in the IM at the level of Ca2+-responsive AH activity. They further imply that urea suppresses PGE synthesis in IM through inhibition of AH and a reduction in the availability of endogenous AA for conversion to PGE.

Localization and partial purification of a neutral-active phospholipase A2 from BCG-induced rabbit alveolar macrophages

The localization and partial purification of a Ca2+-dependent, membrane associated phospholipase A2 (phosphatide 2-acylhydrolase, EC 3.1.1.4) from BCG-induced rabbit alveolar macrophages is described. Phospholipase A activity was determined using autoclaved Escherichia coli, the phospholipids of which were labelled in the 2-acyl position with [1-14C]oleate. Sonicated macrophages or granule preparations exhibited maximal phospholipase A2 activity at pH 7.0, with 5 mM Ca2+. Activity was quantitatively recovered in the pellet after centrifugation of homogenates at 100 000 x g, indicating that the enzyme is membrane-associated. At least two populations of macrophage granules were separated that contained phospholipase A2 activity. Plasma membranes enriched 15-fold with respect to alkaline phosphodiesterase I were devoid of phospholipase activity. The enzyme was purified 1278-fold in a yield of 34%, was active over a broad pH range, and was extremely sensitive to low concentrations of Ca2+. Mg2+ and Mn2+ would not substitute for Ca2+, 1 mM EDTA completely inhibited enzymatic activity. Absolute specificity for the 2-position was demonstrated using 1-[1-14C]stearyl-2-acyl 3-sn-glycerophosphorylethanolamine as substrate. Phospholipase A2 activity was inhibited by the nonsteroidal anti-inflammatory agent indomethacin; the amount of drug required for 50% inhibition was 5 . 10(-4) M.

Isolation and partial characterization of the plasma membrane of purified bovine neutrophils

1. Large amounts of granulocytes can be isolated from bovine blood by differential centrifugation and hypotonic lysis of erythrocytes, followed by separation of neutrophils and eosinophils by centrifugation through a gradient of colloidal silica. 2. Careful homogenization of the purified neutrophils and subfractionation of the postnuclear supernatant by centrifugation through a discontinuous sucrose gradient provides a membrane fraction (at the 20/32%, w/w, sucrose interface), which collects about 20--35% of the activity of plasma membrane marker enzymes. 3. Treatment of the plasma membrane fraction with 0.5 M KCl removes some protein and activity of granule enzymes, leading to an about 20--35-fold enrichment in specific activity of plasma membrane marker enzymes. In particular, there is a 25-fold enrichment in a Ca2+-dependent ATPase, whose half-maximal reaction velocity is reached at 2.2 X 10(-7) M Ca2+. 4. High-resolution sodium dodecyl sulphate/polyacrylamide gel electrophoresis reveals a complex composition of the neutrophil plasma membrane, with about 40 polypeptides stained by Coomassie blue. Ten of these peptides are more intensely stained by the dye; their apparent molecular weight ranges from 81 000 to 34 000. All these ten polypeptides but one (which is likely to be actin) are markedly enriched in the plasma membrane fraction over the original homogenate. 5. Since bovine blood can be obtained in unlimited amounts, the procedures here described can be applied to a large-scale purification of the neutrophil plasma membrane, suitable for biochemical studies.